October 14, 2023

Pfiz­er con­firmed late Fri­day that it will launch a com­pa­ny-wide cost-cut­ting pro­gram this year and next as sales of the drug­mak­er’s Covid vac­cine and an­tivi­ral

The Eu­ro­pean Med­i­cines Agency’s Com­mit­tee for Med­i­c­i­nal Prod­ucts for Hu­man Use (CHMP) this week rec­om­mend­ed sev­en new drugs for au­tho­riza­tion, in­clud­ing Pfiz­er’s po­ten­tial mul­ti­ple myelo­ma

HHS on Fri­day an­nounced its se­lec­tions for the next-gen­er­a­tion of Covid-19 vac­cine can­di­dates to re­ceive $500 mil­lion in fund­ing as part of the gov­ern­ment’s Project

For 10 months, the bio­phar­ma in­dus­try wait­ed to see if Am­gen and Hori­zon Ther­a­peu­tics would pre­vail in their $27.8 bil­lion merg­er fol­low­ing scruti­ny and chal­lenges

While it may ul­ti­mate­ly be im­pos­si­ble to ver­i­fy why ex­act­ly a clin­i­cal-stage biotech would de­lay a po­ten­tial new drug ap­proval, Re­lay Ther­a­peu­tics said yes­ter­day that

No­vo Nordisk is rais­ing its sales and op­er­at­ing prof­it es­ti­mates for the year thanks to its di­a­betes and an­ti-obe­si­ty semaglu­tide prod­ucts We­govy and Ozem­pic, the

Czech biotech So­tio is im­me­di­ate­ly scrap­ping three clin­i­cal tri­als of its in­ter­leukin-15 su­per­ag­o­nist called nan­rilke­fusp al­fa af­ter in­ter­im da­ta showed “in­suf­fi­cient ef­fi­ca­cy.” “While we are

Dig­i­tal phar­ma mar­ket­ing com­pa­ny Op­ti­miz­eRx on Thurs­day said it’s am­pli­fy­ing its di­rect-to-pa­tient ef­forts with the $95 mil­lion ac­qui­si­tion of Medicx Health. Medicx Health, a physi­cian-fo­cused

Af­ter the FDA pub­lished draft guid­ance over the sum­mer on post­mar­ket­ing ap­proach­es to col­lect­ing da­ta from un­der­rep­re­sent­ed groups, stake­hold­er groups large­ly wel­comed the FDA’s pro­pos­als